

## Curriculum Vitae PD Dr. med. Christine E. Brambs



### PD Dr. med. Christine E. Brambs

---

Geburtsdatum, -ort	6. Juli 1978, Ulm
Kontakt	Ismaninger Strasse 22, 81675 München Tel. 089-4140-5437
Familienstand	verheiratet, 2 Söhne, geb. Richter

### Studium

05/2005	3. Staatsexamen, Approbation
2004-2005:	PJ: Yale University, USA; Westmead Hospital, Sydney, Australien; Nepal Medical College, Kathmandu, Nepal
08/2000 - 03/2004	Hochschulfachökonomie Rechnungswesen, AKAD-Hochschule, Bad Rendsburg
09/2001 – 06/2002	Erasmus, Université Libre de Bruxelles, Belgien
10/1998 - 05/2005	Studium der Humanmedizin, Universität Leipzig
08/1997 – 05/1998	Studium generale, McGill University, Montréal, Kanada
1997	Abitur, Humboldt-Gymnasium Ulm

### Berufliche Tätigkeit

Seit 2015	Oberärztin, Frauenklinik der Technischen Universität München
08/2012 – 2015	Fachärztin, Frauenklinik der Technischen Universität München
2014	Schwerpunktbezeichnung gynäkologische Onkologie
02/2013	deutscher Facharzt für Frauenheilkunde und Geburtshilfe
06/2012	schriftlicher Teil der amerikanischen „subspecialty boards“ in der gynäkologischen Onkologie
06/2009 - 06/2012	Fellowship (Subspezialisierung), gynäkologische Onkologie, Yale University School of Medicine, New Haven, CT, USA
07/2009	schriftlicher Teil der amerikanischen „general boards“ in der Gynäkologie und Geburtshilfe
07/2005 - 05/2009	Residency (Facharztausbildung), Department of Obstetrics, Gynecology & Reproductive Sciences, Yale University School of Medicine, New Haven, CT, USA

### Forschung

11/2014	Habilitation, Technische Universität München Titel: Therapieansprechen des Ovarialkarzinoms, Gynäkologisch-onkologische Erkrankungen der Vulva und der Zervix uteri: Mechanismen von Hypoxie und Apoptose
05/2005	Promotion, Universität Leipzig Titel: Charakterisierung der Apoptoseregulatoren Apaf-1 und Caspase-9 im Zervixkarzinom unter Berücksichtigung klinischer und histopathologischer Parameter sowie der intratumoralen Oxygenierung
10/2001– 05/2002	Forschungspraktikum, IRIBHM, Brüssel, Belgien

## Curriculum Vitae PD Dr. med. Christine E. Brambs

Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire, Université Libre de Bruxelles, Brüssel, Belgien

### Arbeitsgruppen

seit 2015 Mitglied der Organkommission Ovar der AGO

### Auszeichnungen

06/2012 José Asis Memorial Award For Her Dedication as a Mentor and Friend From the Yale OB/Gyn Residents, Yale University School of Medicine, New Haven, CT, USA

06/2009 Lee Buxton Resident Research Award For Outstanding Resident Research, Yale University School of Medicine, New Haven, CT, USA

### Sprachkenntnisse

Deutsch Muttersprache

Englisch fließend in Wort und Schrift

Französisch fließend in Wort und Schrift

### Publikationen

#### Originalarbeiten

1. Smits G, Campillo M, Govaerts C, Janssens V, **Richter C**, Vassart G, Pardo L, Costagliola S. Glycoprotein hormone receptors: determinants in leucine-rich repeats responsible for ligand specificity. *EMBO Journal* 2003 Jun 2, 22 (11): 2692-703.
2. Horn LC, Raptis G, Fischer U, Hentschel B, Köhler U, **Richter CE**, Martin R. CD44-v6 concentrations in carcinoma of the uterine cervix: lack of prognostic significance. *Arch Gynecol Obstet.* 2005, 273(2): 104-106.
3. Leo C, **Richter CE**, Horn LC, Schütz A, Pilch H, Höckel M. Expression of Apaf-1 in cervical cancer correlates with lymph node metastasis but not with intratumoral hypoxia. *Gynecol Oncol.* 2005, 97(2): 602-606.
4. Horn LC, Faber S, Eienkel J, Gilks CB, **Richter CE**, Stepan H, Purz S, Krumpke C, Leo C. Der Einsatz von Tissue Microarrays (TMA) – eine neue Technik in der gynäkologischen Tumorforschung. *Geburtshilfe und Frauenheilkunde* 2005, 65: 23-29.
5. Horn LC, Limbach A, Hoepffner W, Tröbs RB, Keller E, Froster UG, **Richter CE**, Jakiubiczka S. Histologic analysis of gonadal tissue in patients with Ullrich-Turner syndrome and derivative Y chromosomes. *Pediatric and Developmental Pathology* 2005, 8: 1-7.
6. Horn LC, **Richter CE**, Hentschel B, Schuetz A, Pilch H, Leo C, Hoeckel M. Juxtatumoral desmoplastic stromal reaction is associated with high tumor cell dissociation in squamous cell carcinomas of the uterine cervix. *Ann Diagn Pathol.* 2006, 10(5): 253-256.
7. Horn LC, Fischer U, Raptis G, Bilek K, Hentschel B, **Richter CE**, Braumann UD, Eienkel J. Pattern of invasion is of prognostic value in surgically treated cervical cancer patients. *Gynecol Oncol.* 2006, 103(3): 906-911.
8. Horn LC, **Richter CE**, Eienkel J, Tannapfel A, Liebert UG, Leo C. p16, p14, p53, cyclin D1, and steroid hormone receptor expression and human papillomaviruses analysis in primary squamous cell carcinoma of the endometrium. *Ann Diagn Pathol.* 2006, 10(4): 193-196.
9. Horn LC, Hentschel B, Bilek K, **Richter CE**, Eienkel J, Leo C. Mixed small cell carcinomas of the uterine cervix: prognostic impact of focal neuroendocrine differentiation but not of Ki-67 labeling index. *Ann Diagn Pathol.* 2006, 10(3): 140-143.

## Curriculum Vitae PD Dr. med. Christine E. Brambs

10. Horn LC, Lindner K, Szepankiewicz G, Edelmann J, Hentschel B, Tannapfel A, Bilek K, Liebert UG, **Richter CE**, Einenkel J, Leo C. p16, p14, p53, and cyclin D1 expression and HPV analysis in small cell carcinomas of the uterine cervix. *Int J Gynecol Pathol.* 2006, 25(2):182-186.
11. Horn LC, Kowalzik J, Bilek K, **Richter CE**, Einenkel J. Clinicopathologic characteristics and subsequent pregnancy outcome in 139 complete hydatidiform moles. *Eur J Obstet Gynecol Reprod Biol.* 2006, 128(1-2): 10-14.
12. Horn LC, Kowalzik J, Bilek K, **Richter CE**, Einenkel J. Prognostic value of trophoblastic proliferation in complete hydatidiform moles in predicting persistent disease. *Pathol Res Pract.* 2006, 202(3): 151-156.
13. Leo C, Horn LC, Rauscher C, Hentschel B, **Richter CE**, Schuetz A, Leo CP, Hoeckel M. Lack of apoptotic protease activating factor-1 expression and resistance to hypoxia-induced apoptosis in cervical cancer. *Clin Cancer Res* 2007, 13(4): 1149-1153.
14. **Richter CE**, Qian B, Martel-M, Yu H, Azodi M, Rutherford TJ, Schwartz PE. Ovarian preservation and staging in reproductive-age endometrial cancer patients. *Gynecol Oncol* 2009, 114(1): 99-104.
15. **Richter CE**, Hui P, Buza N, Silasi DA, Azodi M, Santin AD, Schwartz PE, Rutherford TJ. HER-2/NEU overexpression in vulvar Paget disease: the Yale experience. *J Clin Pathol* 2010;63:544-547.
16. Ratner ES, Tuck D, **Richter C**, Nallur S, Patel RM, Schultz V, Hui P, Schwartz PE, Rutherford TJ, Weidhaas JB. MicroRNA signatures differentiate uterine cancer tumor subtypes. *Gynecol Oncol* 2010;118:251-257.
17. Cocco E, Casagrande F, Bellone S, **Richter CE**, Bellone M, Todeschini P, Holmberg JC, Fu HH, Montagna MK, Mor G, Schwartz PE, Arin-Silasi D, Azoudi M, Rutherford TJ, Abu-Khalaf M, Pecorelli S, Santin AD. Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer. *BMC Cancer* 2010;10:349.
18. Cross SN, Cocco E, Bellone S, Anagnostou VK, Brower SL, **Richter CE**, Siegel ER, Schwartz PE, Rutherford TJ, Santin AD. Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro. *Am J Obstet Gynecol.* 2010;203:162.e1-8.
19. Cocco E, Hu Z, **Richter CE**, Bellone S, Casagrande F, Bellone M, Todeschini P, Krikun G, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Buza N, Pecorelli S, Lockwood CJ, Santin AD. hI-con1, a factor VII-IgGfc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma. *Br J Cancer* 2010;103:812-819.
20. Paik D, Cocco E, Bellone S, Casagrande F, Bellone M, Siegel EE, **Richter CE**, Schwartz PE, Rutherford TJ, Santin AD. Higher sensitivity to Patupilone versus Paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro. *Gynecol Oncol* 2010;119:140-145.
21. **Richter CE**, Cocco E, Bellone S, Silasi DA, Rüttinger D, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. *Am J Obstet Gynecol* 2010;203:582.e1-582.e7.
22. **Richter CE**, Cocco E, Bellone S, Bellone M, Casagrande F, Todeschini P, Rüttinger D, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Primary cervical carcinoma cell lines overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. *Intern J Gynecol Cancer* 2010.
23. **Richter CE**, Santin AD, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE. Urinary hCG screening in the gynecologic oncology population. *Int J Gynecol Surg* 2010.
24. Casagrande F, Cocco E, Bellone S, **Richter CE**, Bellone M, Todeschini P, Siegel E, Varughese J, Arin-Silasi D, Azodi M, Rutherford TJ, Pecorelli S, Schwartz PE, Santin AD. Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of Clostridium perfringens enterotoxin. *Cancer* 2011,15;117(24):5519-28.
25. Ratner ES, **Richter CE**, Minkin MJ, Foran-Tuller KA. How to talk about sexual issues with cancer patients. Beginning the dialogue. *Contemporary OB/GYN* 2012;57(5):40.
26. Horn LC, Mayr D, **Brambs CE**, Einenkel J, Sändig I, Schierle K. Grading of gynecological tumors : Current aspects. *Pathologie* 2016;37(4):337-51.

## Curriculum Vitae PD Dr. med. Christine E. Brambs

27. Horn LC, **Brambs CE**, Handzel R, Mehlhorn G, Schmidt D, Schierle K. Nomenclature of squamous cell precursor lesions of the lower female genital tract : Current aspects. Pathologe 2016 (in press)

### Case reports

---

1. **Richter CE**, Silasi, D-A, Rutherford T. Total abdominal hysterectomy and bilateral salpingo-oophorectomy complicated by post-operative volvulus. J Gynecol Surg 2008, 24 (3): 121-124.
2. **Richter CE**, Saber S, Thung SF. Eclampsia Complicated by Abdominal Compartment Syndrome. Am J Perinatol 2009, 26(10):751-753.

### Abstracts

---

1. **Richter CE**, Cocco E, Bellone S, Casagrande F, Bellone M, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201) in chemotherapy-resistant ovarian cancer cell lines. ASCO Annual Meeting 2010.

### Buchkapitel

---

1. **Richter CE**, Schwartz PE (2012). Fertility preservation in gynecologic malignancies. In Seli E, Agarwal A (Hrsg.), Fertility Preservation. Emerging Technologies and Clinical Applications. New York: Springer Press.
2. **Richter CE**, Schwartz PE (2012). Clinical aspects of gestational trophoblastic disease. In Hui P (Hrsg.), Gestational Trophoblastic Disease. New York: Humana Press.